Show simple item record

dc.contributor.authorDowsett, M
dc.date.accessioned2018-07-11T10:23:52Z
dc.date.issued2004-01
dc.identifier.citationBreast cancer research and treatment, 2004, 87 Suppl 1 pp. S27 - S29
dc.identifier.issn0167-6806
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2029
dc.identifier.eissn1573-7217
dc.identifier.doi10.1007/s10549-004-1580-9
dc.description.abstractTranslational research is intended to efficiently and accurately validate the most promising preclinical biomarkers and ensure that their diagnostic or prognostic potential is rapidly adopted in the clinic. Translational research therefore needs to take into account the biological complexity that is inherent in all cellular pathways, such as the estrogen and progesterone receptor pathways, and yet produce conclusions that will have sufficient statistical power to define and shape clinical practice. This will be achieved through the incorporation of new concepts of trial design, including neoadjuvant or preoperative hypothesis-generating studies, and the increasing use of high-throughput proteomic and genomic approaches. Clinical trials will be increasingly designed to incorporate biomarker analyses, and ongoing trials may employ the retrospective collection of archival tissues to allow the use of prospectively planned biomarker analyses. This approach is being utilized in the TA01 program, which is based upon the 'Arimidex', tamoxifen, alone or in combination (ATAC) trial. The resulting incorporation of new biomarkers and revised trial designs should promote the future development of more precise and increasingly active interventions directed towards the treatment of breast cancer.
dc.formatPrint
dc.format.extentS27 - S29
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectReceptors, Estrogen
dc.subjectReceptors, Progesterone
dc.subjectPrognosis
dc.subjectNeoadjuvant Therapy
dc.subjectProteomics
dc.subjectGenomics
dc.subjectResearch Design
dc.subjectPatient Care Planning
dc.subjectFemale
dc.subjectClinical Trials as Topic
dc.subjectBiomarkers, Tumor
dc.titleDesigning the future shape of breast cancer diagnosis, prognosis and treatment.
dc.typeJournal Article
rioxxterms.versionofrecord10.1007/s10549-004-1580-9
rioxxterms.licenseref.startdate2004-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBreast cancer research and treatment
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublished
pubs.volume87 Suppl 1
pubs.embargo.termsNot known
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record